Migraine with prolonged aura: phenotype and treatment

Michele Viana, Shazia Afridi

Research output: Contribution to journalReview article

Abstract

We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17% of migraine auras are prolonged and that 26% of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume391
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Migraine with Aura
Epilepsy
Phenotype
Therapeutics
Randomized Controlled Trials
Nerve Block
Amiloride
Ketamine
Migraine Disorders
Nose

Keywords

  • Journal Article
  • Review

Cite this

Migraine with prolonged aura : phenotype and treatment. / Viana, Michele; Afridi, Shazia.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 391, No. 1, 01.2018, p. 1-7.

Research output: Contribution to journalReview article

Viana, Michele ; Afridi, Shazia. / Migraine with prolonged aura : phenotype and treatment. In: Naunyn-Schmiedeberg's Archives of Pharmacology. 2018 ; Vol. 391, No. 1. pp. 1-7.
@article{20934f6911a847e7bb5659b04ea84dc3,
title = "Migraine with prolonged aura: phenotype and treatment",
abstract = "We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17{\%} of migraine auras are prolonged and that 26{\%} of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.",
keywords = "Journal Article, Review",
author = "Michele Viana and Shazia Afridi",
year = "2018",
month = "1",
doi = "10.1007/s00210-017-1438-4",
language = "English",
volume = "391",
pages = "1--7",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Migraine with prolonged aura

T2 - phenotype and treatment

AU - Viana, Michele

AU - Afridi, Shazia

PY - 2018/1

Y1 - 2018/1

N2 - We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17% of migraine auras are prolonged and that 26% of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.

AB - We review the published literature on migraine with prolonged aura (PA), specifically with regards to the phenotype and treatment options. PA is not uncommon. A recent study found that about 17% of migraine auras are prolonged and that 26% of patients with migraine with aura have experienced at least one PA. The characteristics of PA are similar to most typical auras with the exception of a higher number of aura symptoms (in particular sensory and/or dysphasic). There are no well-established treatments at present which target the aura component of migraine. Other than case reports, there have been open-label studies of lamotrigine and greater occipital nerve blocks. The only randomised, blinded, controlled trial to date has been of nasal ketamine showing some reduction in aura severity but not duration. A small open-labelled pilot study of amiloride was also promising. Larger randomised, controlled trials are needed to establish whether any of the existing or novel compounds mentioned are significantly effective and safe.

KW - Journal Article

KW - Review

U2 - 10.1007/s00210-017-1438-4

DO - 10.1007/s00210-017-1438-4

M3 - Review article

C2 - 29143861

VL - 391

SP - 1

EP - 7

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 1

ER -